⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6471380 | 0.79 | — | — | |
| SCHEMBL6528452 | 0.67 | — | — | |
| Hydrogen Sulfide SCHEMBL27531910 | 0.62 | TP53 (0.31) | — | |
| Water SCHEMBL27533325 | 0.62 | TP53 (0.31) | — | |
| SCHEMBL1861177 | 0.59 | — | — | |
| SCHEMBL3654178 | 0.59 | — | — | |
| SCHEMBL4757408 | 0.58 | — | — | |
| SCHEMBL3229471 | 0.58 | — | — | |
| Hydrochloric Acid SCHEMBL4574641 | 0.58 | BLM (0.32) | — | |
| SCHEMBL30381295 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| CN-116981675-A | Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitors to E3 ligase ligands and methods of use | 百济神州有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-113880843-B | Heterocyclic compound and application thereof | 武汉朗来科技发展有限公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-114907408-A | Heterocyclic compound, intermediate thereof, preparation method and application thereof | 武汉朗来科技发展有限公司 | 2022-08-16 | — | — | CN | disclosed |
| WO-2022143856-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2022-07-07 | — | — | WO | disclosed |
| CN-114057739-A | Diazepinone derivatives and their use in the treatment of hepatitis b infections | 诺维拉治疗公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-113880843-A | Heterocyclic compound and application thereof | 武汉朗来科技发展有限公司 | 2022-01-04 | — | — | CN | disclosed |
| CN-109641896-B | Diazepinone derivatives and their use in the treatment of hepatitis b infections | 诺维拉治疗公司 | 2021-09-21 | — | — | CN | disclosed |
| CN-107207509-B | Substituted bridged ring urea analogs as sirtuin modulators | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2020-04-21 | — | — | CN | disclosed |
| CN-109641896-A | DIAZEPINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEPATITIS B INFECTIONS | 诺维拉治疗公司 | 2019-04-16 | — | — | CN | disclosed |
| WO-2016126725-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | WO | disclosed |
| WO-2016126722-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | WO | disclosed |
| EP-2788086-A1 | SUBSTITUTED PYRAZOLES AS MGLU5 RECEPTOR MODULATORS | Boehringer Ingelheim International GmbH (DE) | 2014-10-15 | — | — | EP | disclosed |
| WO-2013083591-A1 | SUBSTITUTED PYRAZOLES AS MGLU5 RECEPTOR MODULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-13 | — | — | WO | disclosed |
| EP-2467364-A2 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | Otsuka Pharmaceutical Co., Ltd. (JP) | 2012-06-27 | — | — | EP | disclosed |
| EP-1937272-A2 | BENZODIAZEPINES AS HCV INHIBITORS | Tibotec Pharmaceuticals Ltd. (IE) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007026024-A2 | BENZODIAZEPINES AS HCV INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-03-08 | — | — | WO | disclosed |